Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
  • C12N1/20—Bacteria; Culture media therefor
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/66—Microorganisms or materials therefrom
  • A61K35/74—Bacteria
  • A61K35/741—Probiotics
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
  • A23L29/065—Microorganisms
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/66—Microorganisms or materials therefrom
  • A61K35/74—Bacteria
  • A61K35/741—Probiotics
  • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
  • A61K35/745—Bifidobacteria
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/66—Microorganisms or materials therefrom
  • A61K35/74—Bacteria
  • A61K35/741—Probiotics
  • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
  • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2400/00—Lactic or propionic acid bacteria
  • A23V2400/11—Lactobacillus
  • A23V2400/175—Rhamnosus
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2400/00—Lactic or propionic acid bacteria
  • A23V2400/51—Bifidobacterium
  • A23V2400/529—Infantis
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2400/00—Lactic or propionic acid bacteria
  • A23V2400/61—Propionibacterium
  • A23V2400/617—Freudenreichii

Definitions

• the invention relates to a combination of probiotics, the combination comprising lactobacilli, propionic acid bacteria and/or bifidobacteria in various combinations.
• the probiotics are preferably combined with a suitable prebiotic to produce a synbiotic.
• the combination of the invention may be consumed as such or combined with a suitable foodstuff, such as a dairy product or a drink, and it is therapeutically useful for example for stimulating the immune system and for general health improvement.
• Probiotics are live microbes which, when administered to man or animals, promote the well being of the host by improving the intestinal microbial balance (Fuller, R. Probiotics in man and animals, 1989, J. Appl. Microbiol. 66:365-378).
• the best-documented probiotics include L. rhamnosus LGG, L johnsonii LAI, L casei Shirota and Bifidobacterium lactis Bbl2.
• a number of other probiotics have been described in the literature of the art (see for example M. E. Sanders & J. H. in't Veld 1999. Antonie van Leeuwenhoek 76:293-315, Kluwer Academic Publishers).
• probiotics include the balancing and maintenance of intestinal flora, stimulation of the immune system and anti-carcinogenic activity.
• the useful effects of probiotics in human intestines are based on several factors caused by live bacterial cells, their cell structures and metabolic products. Probiotics are usually administered in nutrients or as capsules.
• a bacterium may be referred to as a probiotic if it essentially meets the following requirements (Lee, Y-K and Saiminen, S. 1995 The coming age of probiotics. Trend Food Sci Technol, 6:241-245): it remains viable in the demanding conditions prevailing in the digestive tract (low pH of the stomach, acids of the digestive system, etc.); attaches to the walls of the intestine; metabolizes in the intestine; is technologically applicable (endures processing); exhibits clinically tested and reported health effects; and is safe to consume.
• Prebiotics are nondigestible food ingredients which promote the health of humans by selectively stimulating the growth and activity of one or some probiotic bacteria in the colon (Gibson, G.R. and Roberfroid, M.B. 1995. Dietary modulation of the human colonic microbiota - introducing a concept of prebiotics. J. Nutr. 125:1401-1412).
• a prebiotic is usually a nondigestible carbohydrate (oligo- or polysaccharide) or a sugar alcohol which is not degraded or absorbed in the upper digestive tract.
• a synbiotic is defined as a combination of a prebiotic and a probiotic, the prebiotic promoting the viability of the added microbe and its attachment to the intestine, thereby promoting health (Gibson and Roberfroid 1995, supra).
• FOS structural-oligosaccharide
• TOS transgalacto-oligosaccharides
• the primary fatty acids produced in fermentation are acetic acid, butyric acid and propionic acid (Cummings, J.H. Short-chain fatty acids, in: Human Colonic Bacteria: Role in Nutrition, Physiology and Pathology, G.R. Gibson and G.T. Macfarlane (eds.), pp. 101 - 130, CRC Press, Boca Raton, 1995).
• An increase in the number of short-chain fatty acids would be generally advantageous.
• Nondigestible carbohydrates are the principal substrate for colonic microbes, although they also may include compounds the intestinal fermentation of which is disadvantageous (Gibson and Roberfroid, 1995, supra). [0006] Human digestive tract accommodates a plural number of bacteria which live in symbiosis with the host.
• the number of species Lactobacillus, Streptococcus, Fusobacterium, Veillonella, Propionibacterium and Enterobacteriaceae is slightly less. Some of the species represent useful microbes, whereas others may even be harmful.
• the average microbial content in feces is 10 12 cfu/g (per dry matter). Bacteria degrade and ferment those food ingredients in the colon, which are not absorbed in the small intestine, the end products of the fermentation being absorbed in the intestine for use by the body. In addition to nutrition, the microbial balance of the colon is of major significance to the state of health of a man (Tannock, G.W. 1998. Studies of the intestinal microflora: A prerequisite for the development of probiotics, Int.
• the ⁇ -glucuronidase enzymes produced by intestinal bacteria are assumed to contribute to the formation of carcinogenic compounds, for example.
• Steroids and other carcinogenic compounds metabolize in the liver and then conjugate with glucuronic acid.
• the bile delivers the conjugated glucurone compound to the small intestine and from there the compound passes further to the colon where the glucuronidase enzymens can hydrolyse the compound, thereby releasing toxic compounds into the colon (Rowland, I.R. 1995.
• Toxicology of the colon role of the intestinal microflora, in: Human Colonic Bacteria, Role in nutrition, physiology, and pathology. Editors: Gibson, G.R. and Macfarlane, G.T., pp.
• glycosides originating from vegetables and tea are not absorbed in the small intestine and pass to the colon, where they may be hydrolysed by the action of ⁇ -glucosidases to form toxic or mutagenic aglycone compounds (Goldin, B.R. 1990. Intestinal Microflora: metabolism of drugs and carcinogens. Annals of Medicine 22:43-48).
• the intestinal flora produces urease enzyme which degrades urea into ammonia.
• High amounts of ammonia may be toxic to the epithel cells of the intestine (Mobley, H.L.T. and Hausinger, R.P. 1989. Microbial ureases: significance, regulation and molecular characterization. Microbiological Reviews 53:85-108).
• Publication EP 904 784, N. V. Nutricia describes a probiotic product containing Bifidobactenum, Enterococcus faecium and Lactobacillus.
• the product may contain prebiotics, such as polysaccharide or non-degradable starch, and immunoglobulines, vitamines, etc.
• the product has a health- promoting effect in that it stimulates the immune system, for example. The effect has not, however, been shown in clinical tests, neither has any other biological activity been studied.
• WO 00/33854 N. V. Nutricia
• the probiotics particularly referred to are Lactobacillus and Bifidobactenum, although Pediococcus, Propionibacterium, Leuconostoc and Saccharomyces are also mentioned.
• the prebiotics involved include transgalactooligosaccharides (TOS) and fructooligosaccharides (FOS).
• TOS transgalactooligosaccharides
• FOS fructooligosaccharides
• a particularly advantageous combination comprises Lactobacillus rhamnosus and a transgalactooligosaccharide or a hydrolysis product of potato galactane, this combination and its preparation being also illustrated in the examples.
• the product has health-promoting effects and it is particularly useful in the treatment of intestinal disorders. However, its activity has not been demonstrated in any way.
• WO 97/34615 University of New South Wales, describes a probiotic composition containing, in addition to one or more probiotics, resistent (non-degradable) starch and oligosaccharide, a synergistic effect being obtained between the three components.
• the probiotics mentioned are Saccharomyces, Bifidobactenum, Bacteroides, Clostridium, Fusobacterium, Propionibacterium, Lactococcus, Streptococcus, Enterococcus, Staphylococcus, Peptostreptococcus and Lactobacillus, and the oligosaccharides include, among many others, fructo- and galactooligosaccharides.
• the composition comprises altogether 4 to 20 parts by weight of probiotics and 5 to 22 parts by weight of oligosaccharides, of which for example galacto- and fructooligosaccharides, inuline in particular, are mentioned.
• the probiotics mentioned include Bifidobactenum breve, Bifidobactenum infantis, Bifidobactenum longum, Bifidobactenum bifidum, Lactobacillus acidophilus, Lactobacillus bulgaricus, Lactobacillus casei, Lactobacillus plantarum, Streptococcus thermophilus and Streptococcus faecium.
• a mixture containing probiotics and prebiotics can be added to milk-based desserts, milks or juices to balance the functioning of the intestine. Any biological activity of the combination has not, however, been described.
• PAB-milk which comprises three bacterial strains: Propionibacterium freudenreichii subsp. shermanii MTCC 1371 , Lactobacillus acidophilus R. and Bifidobactenum bifidum NDRI. Prebiotics have not been added to the product. According to the publication, PAB-milk is suitable for babies and children, also for those suffering from lactose intolerance.
• WO 99/10476 describes the stimulating effect of specific bacterial strains, i.e. Lactobacillus rhamnosus HN001 (NM97/09514) and HN067 (NM97/01925), and Lactobacillus acidophilus HN017 (NM97/09515) and Bifidobactenum lactis HN019 (NM97/09513), on the immune system, measured as enhanced phagocytosis.
• the strains can be used individually, or added to dairy products or pharmaceutical preparations.
• US 5,902,578, Abbott Laboratories relates to a method for preventing and treating diarrhea with a mixture of Lactobacillus reuterii, Lactobacillus acidophilus and Bifidobactenum infantis, the mixture being prepared as a powder, liquid or pills.
• WO 97/29762 and WO 97/29763 Procter & Gamble Company
• lactobacilli and bifidobacteria combined with galacto- or fructooligosaccharides together with a plant of the genus Ericaceae, or an extract thereof for the treatment of urinary tract infections and intestinal disorders
• WO 00/29007, Reddy describes the combining of probiotics, such as Lactococcus, Lactobacillus, Pediococcus, Streptococcus, Propionibacterium, Brevibacterium, Penicillium and Saccharomyces with herb- based natural products and drug-like substances.
• probiotics and synbiotics have been extensively studied, good and versatile commercial products are not available to any significant extent. Consequently, there is continued, evident need to offer the consumers new products having clearly demonstrated probiotic effects and produced in a form that allows them to be used as a convenient part or supplement, for example, of the every-day diet.
• the present invention is thus based on a new combination comprising (2) lactobacilli strains, a propionic acid bacterium and/or a bifidobacterium.
• the combination preferably comprises a prebiotic supporting the growth of the above- mentioned microbes.
• lactobacilli two strains of lactobacilli are mainly used, i.e. Lactobacillus rhamnosus LGG (ATCC 53103) and Lactobacillus rhamnosus LC705 (DSM 7061).
• the propionic acid bacterium is usually Propionibacterium freudenreichii ssp. shermanii PJS (DSM 7067).
• the bifidobacterium may be any bifidobacterium having a probiotic effect, typically strains belonging to the species Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium bifidum and Bifidobacterium adolescentis are used. [0026] At least three of these bacteria are usually included, and the combination preferably includes Lactobacillus rhamnosus LGG and/or Propionibacterium freudenreichii ssp. shermanii PJS.
• the most preferred combination is a mixture of four strains, Lactobacillus rhamnosus LGG (ATCC 53103), Lactobacillus rhamnosus LC705 (DSM 7061), Propionibacterium freudenreichii ssp. shermanii PJS (DSM 7067) and Bifidobacterium infantis Bbi99 (DSM 13692).
• any bifidobacterium such as Bbl2
• the prebiotic used is preferably galactooligosaccharide (GOS).
• Another preferred composition is a combination of a bifidobacterium and a propionic acid bacterium, in which any bifidobacterium can be used together with Propionibacterium freudenreichii ssp. shermanii PJS (DSM 7067).
• the new combination can be used as such or as a part of another product, such as a pharmaceutical or a food product.
• the combination of the invention has an advantageous effect on the human intestinal balance in that it increases the entero-lactone production and reduces a disadvantageously high pH value.
• the combination also influences the immune response by increasing the amount of lymphocytes and that of ⁇ -interferon (IFN) and by reducing the formation of carcinogenic substances.
• IFN ⁇ -interferon
• the combination of the invention is thus useful for the prevention and treatment of intestinal disorders, allergies and cancer and for promoting general health.
• the combination is thus also applicable as a therapeutic substance and in the preparation of therapeutic substances.
• Lactobacillus rhamnosus GG (LGG), Lactobacillus casei ssp. rhamnosus LC705 and Propionibacterium freudenreichii ssp. shermanii JS (PJS) have been described in the prior art.
• Bifidobacterium infantis Bbi99 which may be included in the combination, is a new strain and will be described in greater detail below.
• Lactobacillus rhamnosus GG (LGG) is described for example in US Patent 5,032,399, Gorbach & Goldin.
• the strain is isolated from human feces, it is able to grow well in pH 3 and survives even lower pH values as well as high bile acid contents.
• the strain exhibits excellent adhesion to both mucus and epithelial cells. Lactic acid yield from glucose is good: when grown in MRS broth, the strain produces 1.5 - 2% of lactic acid. The strain does not ferment lactose and thus it does not produce lactic acid from lactose.
• the strain employs the following carbohydrates: D-arabinose, ribose, galactose, D-glucose, D- fructose, D-mannose, rhamnose, dulcitol, inositol, mannitol, sorbitol, N- acetylglucosamine, amygdalin, arbutin, esculin, salicin, cellobiose, maltose, saccharose, trehalose, melezitose, gentibiose, D-tagatose, L-fucose, and gluconate.
• the strain grows well at +15 - 45°C, the optimum temperature being 30 - 37°C.
• Lactobacillus rhamnosus GG is deposited with the depository authority American Type Culture Collection under accession number ATCC 53103.
• DSM Zellkulturen GmbH
• the combination of the invention may also include other microorganisms, such as microorganisms and probiotics contained in starters used in the dairy industry. There are numeral well-documented strains of starters, which are commercially available from producers such as Hansen
• the microorganisms are cultivated using processes conventional in the art. They can be cultivated as pure cultures or as different mixed cultures. The cultures can be used as such or they may be processed as desired for example by purifying, concentrating, lyophilising or finishing them to produce various preparations.
• a sufficient amount of probiotics is used in the combination to produce the desired probiotic effect.
• the amount of each probiotic may thus vary within a broad range, depending on, for example, the strains used and their number, the total amount of cells of the probiotics, the total daily dose, and on other properties and ingredients of the product.
• a daily dose of the combination usually comprises about 10 6 -10 10 cfu of probiotics.
• One or more prebiotics are preferably added to the combination to form a synbiotic.
• the prebiotic is selected according to the microorganisms included in the combination concerned such that it will support the growth of the microorganisms. Suitable prebiotics may include e.g.
• oligosaccharides particularly galactooligosaccharide (GOS), palatinoseoligosaccharide, soybean oligosaccharide, gentiooligosaccharide, xylooligomers, non-degradable starch, lactosaccharose, lactulose, lactitol, maltitol, polydextrose, or the like.
• GOS galactooligosaccharide
• palatinoseoligosaccharide palatinoseoligosaccharide
• soybean oligosaccharide gentiooligosaccharide
• xylooligomers non-degradable starch
• lactosaccharose lactulose
• lactitol lactitol
• maltitol polydextrose, or the like.
• a sufficient amount of the prebiotic is added to the synbiotic to produce a prebiotic effect. What is a sufficient amount is determined for example according to the strain concerned, the amount of
• the prebiotic does not necessarily need to be included in the combination. Depending on the end product and the purpose of use, it may be better to consume the prebiotic separately, although approximately at the same time with the probiotic combination. In some cases it may suffice to only consume the probiotic combination, the prebiotic being thus not needed at all.
• An example of this is a case where the intestinal conditions of the host are suitable for the growth of probiotics without an added prebiotic being needed, and when the prebiotic is contained in the normal diet (if it is consumed in porridge or rye bread, for example).
• the present invention has shown that the microorganisms used meet the criteria set for probiotics: they survive well in the demanding conditions of the digestive tract, adhere well to intestinal cells and multiply well in the intestines. They have also been shown to exhibit excellent biological effects; for example, they increase the number of microorganisms desirable from the point of view of health and reduce the number of harmful microorganisms in the intestine, they reduce the activity of harmful enzymes and thereby the formation of harmful, or even carcinogenic, substances, and they have a stimulating effect on the immune response.
• the combination of the invention can be used as such or in the form of capsules, pills or tablets, for example, manufactured in conventional processes of preparing pharmaceutical products.
• the combination of the invention may also be added to diverse edible products, such as foodstuffs, products of the beverage or confectionery industry, health- promoting products, natural products, etc.
• products containing the combination of the invention such as dairy products, particularly yogurts and other fermented milk products; cheeses and spreads; children's food; juices and soups; and capsules are preferred.
• a product in the form of a capsule usually only contains the probiotic combination, the prebiotic being consumed separately.
• the end products are prepared in conventional processes, the combination being added either in connection with the preparation or thereafter, during the finishing of the end product.
• the combination was prepared from a bacterial mixture, adding, when desired, galacto-oligosaccharide (GOS) as a prebiotic.
• the bacterial mixture was formed from bacterial cultures (concentrates or freeze- dried powders) of four strains, i.e. Lactobacillus rhamnosus LGG (ATCC 53103), Lactobacillus rhamnosus LC705 (DSM 7061), Propionibacterium freudenreichii ssp. shermanii PJS (DSM 7067) and Bifidobacterium infantis Bbi99 (DSM 13692).
• GOS galacto-oligosaccharide
• LGG was cultivated in a medium comprising 5.0% of whey permeate (Valio Oy), 0.5% of casein hydrolysate (Valio Oy), 0.5% of technical yeast, and 0.0015% of MnS0 4 x H 2 O.
• the components of the medium were dissolved into water and the medium was sterilized (for 20 min at 120°C).
• the cultivation was carried out at a temperature of 37°C and a pH of 5.8 (adjusted with NH OH) for about 18h and at a mixing rate of 100 rpm.
• the bacterial cells were concentrated, washed and freeze-dried using a 10% (v/v) protective agent supplement, such as a saccharose broth of 46%, or a similar alternative known to those skilled in the art.
• a 10% (v/v) protective agent supplement such as a saccharose broth of 46%, or a similar alternative known to those skilled in the art.
• the final bacterial content was >1x10 9 cfu/ml in the cultivation, >1x10 10 cfu/g in the concentrate and >1x10 11 cfu/g in the freeze-dried powder.
• composition of the growth medium of bifidobacteria was the following: whey permeate 4% (Valio Ltd.), casein hydrolysate 1.0% (Valio Ltd.), technical yeast extract 1.0% (LAB M), cystein-HCI 0.03% (Merck, Darmstadt, Germany). Other ingredients of the medium were first dissolved into water, then the cystein-HCI was added and the medium was sterilized (for 20 min at 120°C). The cultivation was carried out in about 18-20 hours at a temperature of 37°C and a pH of 6.7 (adjusted with NH 4 OH) and at a mixing rate of 100 rpm. The bacterial content of the cultivation was >1x10 9 cfu/ml.
• the bacteria cells were concentrated, washed and freeze-dried using a 10% (v/v) protective agent supplement, such as a saccharose broth of 46%, or a similar alternative known to those skilled in the art.
• a 10% (v/v) protective agent supplement such as a saccharose broth of 46%, or a similar alternative known to those skilled in the art.
• the bacterial content in the concentrate was >1x10 10 cfu/g and in the freeze-dried powder >1x10 11 cfu/g.
• LC705 and PJS were cultivated together by inoculating bacterial cells to a whey-based growth broth in a ratio of 1:2.
• the whey-based growth medium contained 3.5 - 5% of whey permeate (Valio Oy), 1.0% of caseinhydrolysate and 1.0% of yeast extract (Valio Oy).
• the strains were cultivated for three days at 30°C with the pH maintained at 4.5 by means of an automated pH adjustment. After the cultivation, the content of each bacterial strain was >1x10 9 cfu/ml.
• the strains may also be cultivated separately. In that case LC 705 is cultivated as described above in connection with the joint cultivation, only the cultivation time is 1 day at 30°C.
• PJS is cultivated in a whey-based growth medium comprising 2% of whey permentate, 1.0% of casein- hydrolysate and 1% of yeast extract. The strain is cultivated for 3 days at 30°C in a pH value of 6.3, after which the process is carried out as above.
• the concentrates or the powders are mixed in a ratio of
• the mixing ratio is 1 :1 :1:1.
• the obtained mixture of concentrates or freeze-dried powders is used as a probiotic portion in the different product applications of the combination.
• the mixture is added to the product application to obtain the following final bacteria content in the product:
• GOS Valio Oy
• LC705 is known to adhere well to epithel cells, similarly as LGG (Lehto, E. and Saiminen S. 1997. Adhesion of two lactobacillus strains, one lactococcus strain and one propionibacterium strain to cultured human intestinal CaCO-2 cell lines. Bioscience Microflora 16: 13 - 17). This property is beneficial when there is an imbalance in the intestine and the protective mucus has been weakened.
• the strains were tested at different pH values in MRS broths the pH of which had been adjusted with lactic acid to values pH 4, pH 3 and pH 2.
• the strain to be studied fresh culture was inoculated into a pH broth of 1% and grown at 37°C for 3 hours, after which the content of live cells was determined using an agar suitable for the strain (see Table 5).
• the strains maintained their viability in the 3-hour process in a pH value of 3 excellently.
• the propionic bacterium remained viable even in pH 2.
• the bacteria were not protected by components carried by food (such as fat) and therefore they may be assumed to preserve even better when consumed in vivo together with food.
• the strains were tested in MRS broths that contained 0.3% and 0.5% of Oxgal (Sigma) bile salt by inoculating 1% of the fresh culture into the bile salt MRS broth to be studied.
• the strains were cultivated in the broths for 3 hours at 37°C, after which the content of live cells was determined using an agar suitable for the strain (see Table 5). All strains survived the treatment excellently.
• Corresponding juice with no added GOS syrup or bacterial mixture was used as a control.
• LGG > 10' cfu/ml LC705 > 10 7 cfu/ml PJS > 10 8 cfu/ml Bbi99 > 10 7 cfu/ml
• the drink described in example 4 which contained the above described probiotic combination (Pro) or the probiotic combination and a prebiotic (Syn), was clinically tested on 20 males.
• the test persons took the drink daily in accordance with the study plan and during the study they were not allowed to consume any other probiotic-containing product.
• the study scheme was such that the test started with a run-in period continued by a probiotics period of two weeks and a subsequent synbiotics period, and it ended with what is known as a wash-out period.
• Microbes and enzymes were analysed from the feces samples and enterolactone content and immune response from the blood.
• the total lactic acid bacterial content, LGG, LC705, the total propionic acid bacterial content, PJS, and the total bifidobacteria content were determined applying methods known in the art and the parameters shown in Table 5.
• ⁇ -glucuronidase and ⁇ -glucosidase were determined as described by Freeman (Freeman, H. J. 1986. Effects of differing purified cellulose pectin, and hemicellulose fibre on faecal enzymes in 1,2-dimethyl - hydrazine-induced rat colon carcinogenesis. Cancer Research 46: 5529 - 5532) and urease according to the instructions of the manufacturer (Boehringer Mannheim cat. no. 542946).
• Metabolism of glucosidase and glucuronidase produces carcinogenic compounds.
• the significant decrease in enzyme activity produced by the probiotic and synbiotic combinations of the invention clearly demonstrate a positive effect with regard to the decreasing of the formation of carcinogenic substances.
• Enterolactone content was determined using the method of Adlercreutz et al. (Adlercreutz, H., Fostis, T., Lampe, J., Wahala, K., Makela, T., Brunow, G. and Hase, T. 1993. Quantitative determination of lignans and isoflavonoids in plasma of omnivorous and vegetarian women by isotope dilution gas-chromatography mass-spectrometry. Scan J. Clin Lab Invest 53: 5 - 18.)
• enterolactone levels of test persons with an initial enterolactone level of ⁇ 10 nmol/l increased significantly as a result of the synbiotic intake (to a level of 11.2).
• Enterolactone content has been shown to clearly correlate with the risk of getting cancer: the higher the content, the lower the risk. This result thus also shows the beneficial effect of the probiotic and synbiotic combinations of the invention to a decreased cancer risk.
• Lymphocyte function was studied before the intake of the synbiotic product was started and after 4 weeks after the intake had been started.
• lymphocyte function was studied as follows: [0078] Lymphocytes were isolated from peripheral blood using
• the lymphocytes were stimulated with PHA mitogen (Sigma) in RPMI cultivation broth (National Public Health Institute; department of nutrient broths) which contained 5% of inactivated AB+ serum (Finnish Red Cross) and L-glutamine. After 48 hours, cell culture medium was collected for cytokine determination from four adjacent culture wells having a cell density of 200 000 cells per 200 ⁇ l of culture broth in the well, either with or without the mitogen. The cells were harvested after 16 hours from the adding of thymidine and the incorporation into DNA (cpm) of radioactive thymidine was measured. The contents of cytokines IL-4, IL-5, TGF- ⁇ 1 and IFN- ⁇ were determined from the cell culture broths by using the ELISA method.
• IFN- ⁇ belongs to what are known as Th1 cytokines, which strengthen cytotoxic lymphocyte function and are antagonists of IL-4 and TGF- ⁇ 1 cytokines. Low IFN- ⁇ secretion has been reported for persons prone to allergies. In addition, children with a predisposition to atopy and allergy reactions have been presumed to suffer from slow maturing of IFN- ⁇ secretion. The significant stimulating effect of the combinations of the invention on IFN- ⁇ secretion thus proves their efficiency in the prevention and treatment of allergies.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Molecular Biology (AREA)
• Organic Chemistry (AREA)
• Food Science & Technology (AREA)
• Nutrition Science (AREA)
• Polymers & Plastics (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Biotechnology (AREA)
• Genetics & Genomics (AREA)
• Virology (AREA)
• Biomedical Technology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Biochemistry (AREA)
• General Engineering & Computer Science (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Jellies, Jams, And Syrups (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (17)

Applications Claiming Priority (2)

Publications (3)

Family

ID=8560139

Family Applications (1)

Country Status (24)

Cited By (34)

Families Citing this family (66)

Citations (4)

Family Cites Families (19)

• 2001
  • 2001-01-25 FI FI20010157A patent/FI109602B/fi not_active IP Right Cessation
• 2002
  • 2002-01-17 PT PT02710896T patent/PT1359816E/pt unknown
  • 2002-01-17 BR BRPI0206689A patent/BRPI0206689B1/pt not_active IP Right Cessation
  • 2002-01-17 RU RU2003125858/13A patent/RU2291899C2/ru not_active IP Right Cessation
  • 2002-01-17 PL PL363366A patent/PL204245B1/pl unknown
  • 2002-01-17 AU AU2002229787A patent/AU2002229787B2/en not_active Ceased
  • 2002-01-17 NZ NZ527172A patent/NZ527172A/en not_active IP Right Cessation
  • 2002-01-17 WO PCT/FI2002/000035 patent/WO2002060276A1/en not_active Ceased
  • 2002-01-17 EE EEP200300351A patent/EE05299B1/xx not_active IP Right Cessation
  • 2002-01-17 HR HR20030586A patent/HRP20030586B8/xx not_active IP Right Cessation
  • 2002-01-17 DK DK02710896T patent/DK1359816T3/da active
  • 2002-01-17 KR KR10-2003-7009902A patent/KR20040012717A/ko not_active Ceased
  • 2002-01-17 CA CA2434337A patent/CA2434337C/en not_active Expired - Fee Related
  • 2002-01-17 EP EP02710896A patent/EP1359816B1/en not_active Expired - Lifetime
  • 2002-01-17 US US10/470,151 patent/US8309073B2/en not_active Expired - Fee Related
  • 2002-01-17 ES ES02710896T patent/ES2243697T3/es not_active Expired - Lifetime
  • 2002-01-17 JP JP2002560478A patent/JP3984546B2/ja not_active Expired - Fee Related
  • 2002-01-17 HU HU0401017A patent/HU225790B1/hu not_active IP Right Cessation
  • 2002-01-17 CN CNB028041178A patent/CN100400645C/zh not_active Expired - Fee Related
  • 2002-01-17 AT AT02710896T patent/ATE297664T1/de active
  • 2002-01-17 CZ CZ20031915A patent/CZ301673B6/cs not_active IP Right Cessation
  • 2002-01-17 DE DE60204662T patent/DE60204662T2/de not_active Expired - Lifetime
• 2003
  • 2003-07-15 ZA ZA200305458A patent/ZA200305458B/en unknown
  • 2003-07-21 NO NO20033283A patent/NO325463B1/no not_active IP Right Cessation

Patent Citations (4)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events